title: A. actinomycetemcomitans LPS enhances foam cell formation induced by LDL.
abstract: The objective of this study was to examine whether native low-density lipoprotein (LDL) induces foam cell formation by macrophages and to examine the effect of lipopolysaccharide (LPS) on native LDL-induced foam cell formation by macrophages in vitro. RAW 264.7 cells were cultured with LDL or high-density lipoprotein (HDL) in the presence of LPS derived from Aggregatibacter actinomycetemcomitans. Foam cell formation was determined by staining with Oil-red-O to visualize cytoplasmic lipid droplet accumulation. The expression of LDL-receptor and the degree of internalization of FITC-conjugated LDL in RAW 264.7 cells were examined by immunofluorescence microscopy. The images were digitally recorded and analyzed with Image J software. Statistical analysis was performed by JMP software. Foam cell formation was induced by the addition of native LDL in dose- and time-dependent manners, whereas HDL showed no effect. LPS enhanced the foam cell formation induced by native LDL. In addition, LPS stimulated the expression of LDL-receptor protein on RAW 264.7 cells and enhanced the internalization of LDL. The enhancement of foam cell formation induced by LPS and LDL was inhibited by the depolymerizing agent nocodazole and amiloride analog 5-(N-ethyl-N-isoprophyl) amiloride (EIPA). Our findings indicate that LPS plays an important role in foam cell formation by LDL-stimulated macrophages.
authors: Division of Infections and Molecular Biology, Department of Health Promotion, Kyushu Dental University, 2-6-1 Manazuru Kokurakita-ku, Kitakyushu 803-8580, Japan.
authors: M
authors: M
authors: Morishita
authors: W
authors: W
authors: Ariyoshi
authors: T
authors: T
authors: Okinaga
authors: M
authors: M
authors: Usui
authors: K
authors: K
authors: Nakashima
authors: T
authors: T
authors: Nishihara
mesh_terms: D062646:Acid Sensing Ion Channel Blockers / Q000494:pharmacology; D016976:Aggregatibacter actinomycetemcomitans / Q000737:chemistry / Q000502:physiology*; D000584:Amiloride / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D002460:Cell Line; D004357:Drug Synergism; D005487:Foam Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000494:pharmacology* / Q000502:physiology; D008264:Macrophages / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008870:Microtubules / Q000187:drug effects; D015739:Nocodazole / Q000494:pharmacology; D010518:Periodontitis / Q000382:microbiology; D010873:Pinocytosis / Q000187:drug effects*; D011973:Receptors, LDL / Q000096:biosynthesis*; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D050257:Tubulin Modulators / Q000494:pharmacology*
chemical_list: D062646:Acid Sensing Ion Channel Blockers; D008070:Lipopolysaccharides; D008077:Lipoproteins, LDL; D011973:Receptors, LDL; D017923:Sodium-Hydrogen Exchangers; D050257:Tubulin Modulators; D000584:Amiloride; D015739:Nocodazole; C039614:ethylisopropylamiloride